NCT01140737 (Axi-STS) is a Phase 2 clinical trial of Axitinib in Soft Tissue Sarcoma, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.

Who is sponsoring NCT01140737?

NCT01140737 is sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.

What drugs are being tested in NCT01140737?

Interventions in NCT01140737: Axitinib.

What condition does NCT01140737 study?

NCT01140737 studies Soft Tissue Sarcoma.

Is NCT01140737 still recruiting?

NCT01140737 is currently completed. Last updated 18 March 2021.

Last reviewed 2021-03-18 · How we verify

NCT01140737: Axi-STS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas

Completed Phase 2 Last updated 18 March 2021

What this trial tests

Phase 2 trial testing Axitinib in Soft Tissue Sarcoma in 145 participants. Completed in 8 January 2019.

Timeline

31 August 2010

Primary endpoint
11 June 2016

8 January 2019

Quick facts

Lead sponsor	Sheffield Teaching Hospitals NHS Foundation Trust
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	145
Start date	31 August 2010
Primary completion	11 June 2016
Estimated completion	8 January 2019
Sites	13 locations across United Kingdom

Drugs / interventions tested

Axitinib — full drug profile →

Conditions studied

Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Who can join

16 and older, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study objective is to evaluate the therapeutic activity, safety and tolerability of axitinib in patients with advanced/metastatic soft tissue sarcoma who are unsuitable for or have relapsed after standard chemotherapy. The therapeutic activity will be separately assessed in angiosarcoma, synovial sarcoma, leiomyosarcomas and other sarcomas.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.
Murali R, Chandramohan R, Möller I, Scholz SL, et al · · 2015 · cited 107× · PMID 26440310 · DOI 10.18632/oncotarget.5936
Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.
Nguyen TH, Barr FG. · · 2018 · cited 54× · PMID 30373318 · DOI 10.3390/molecules23112798
Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities.
Anderson JL, Denny CT, Tap WD, Federman N. · · 2012 · cited 42× · PMID 22546864 · DOI 10.1038/pr.2012.54
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update.
Young RJ, Woll PJ. · · 2017 · cited 24× · PMID 29250195 · DOI 10.1007/s12254-017-0365-x
The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.
Rocchi L, Caraffi S, Perris R, Mangieri D, et al · · 2014 · cited 19× · PMID 25236925 · DOI 10.1042/bsr20140075

Verify or expand the search:

Other trials of Axitinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06161558 — Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors · Phase 1 · withdrawn
NCT06690697 — Combination of Toripalimab and JS004 Therapy for ccRCC · Phase 2 · recruiting
NCT05176288 — Avelumab, Palbociclib and Axitinib in Advanced RCC · Phase 2 · withdrawn

Other recruiting trials for Soft Tissue Sarcoma

Currently open trials in the same condition.

NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting

Other Sheffield Teaching Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

NCT07407712 — Better Outcomes Through Optimal Sleep in Surgical Training · NA · recruiting
NCT07172555 — Virtual Dietetic Interventions in Patients With Coeliac · NA · recruiting
NCT06310993 — Exercise to Boost Immunity in Advanced Cancer · NA · not yet recruiting
NCT06905405 — The Use of Advanced Imaging in HFpEF · recruiting
NCT06633627 — Neurological Responses in Patients with Dentine Hypersensitivity · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01140737 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheffield Teaching Hospitals NHS Foundation Trust
Last refreshed: 18 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01140737.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing